Inflammatory Bowel Disease Market to Witness Upsurge in Growth During the Forecast Period | Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-la Roche, Genentech, Abbvie, Boehringer Ingelheim

Posted on
by

Inflammatory Bowel Disease Market to Witness Upsurge in Growth During the Forecast Period | Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-la Roche, Genentech, Abbvie, Boehringer Ingelheim
Inflammatory Bowel Disease Therapeutics Market
According to DelveInsight, the Inflammatory Bowel Disease (IBD) therapeutics market is expected to undergo significant growth in the coming years due to the anticipated launch of investigational drugs and the increasing incidence of IBD. The IBD treatment pipeline is currently robust, featuring numerous key assets in the late stages of development. Some of the most promising emerging therapies include Mirikizumab, Filgotinib, and others.

DelveInsight’s “Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Inflammatory Bowel Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Inflammatory Bowel Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Recent Breakthroughs in the Inflammatory Bowel Disease Market:

  • In September 2023, Cosmo Pharmaceuticals and Adalvo have entered into a license and supply agreement for Rifamycin SV with MMX technology across Europe, Asia-Pacific (APAC), Middle East/North Africa (MENA), and Latin America (LATAM) regions.

  • In May 2023, NGM Biopharmaceuticals announced that findings from a Phase II investigator-sponsored trial of aldafermin for treating patients with idiopathic bile acid malabsorption (BAM) alongside irritable bowel syndrome with diarrhea (IBS-D) were presented at Digestive Disease Week 2023.

Inflammatory Bowel Disease Overview

Inflammatory Bowel Disease (IBD) refers to a group of disorders that cause chronic inflammation of the gastrointestinal (GI) tract. The two main types of IBD are Crohn’s disease and ulcerative colitis.

Crohn’s Disease

  • Location: Can affect any part of the GI tract from the mouth to the anus, but most commonly affects the end of the small intestine (ileum) and the beginning of the colon.

  • Characteristics: Inflammation can occur in patches and can penetrate through multiple layers of the bowel walls.

  • Symptoms: Abdominal pain, diarrhea (sometimes with blood), weight loss, and fatigue.

Ulcerative Colitis

  • Location: Limited to the colon (large intestine) and rectum.

  • Characteristics: Inflammation is continuous and affects only the innermost lining of the colon.

  • Symptoms: Bloody diarrhea, abdominal pain, urgency to defecate, and weight loss.

Common Symptoms of IBD

  • Persistent diarrhea

  • Abdominal pain and cramping

  • Rectal bleeding

  • Fatigue and loss of energy

  • Weight loss

  • Reduced appetite

Causes and Risk Factors

The exact cause of IBD is unknown, but it is believed to result from a combination of factors:

  • Genetics: A family history of IBD increases the risk.

  • Immune System: An abnormal immune response can trigger inflammation in the GI tract.

  • Environmental Factors: Diet, smoking, and use of nonsteroidal anti-inflammatory drugs (NSAIDs) may contribute.

Diagnosis

  • Blood Tests: To check for anemia or infection.

  • Stool Tests: To rule out infections and detect inflammation.

  • Endoscopic Procedures: Colonoscopy and sigmoidoscopy to visualize the GI tract and take biopsies.

  • Imaging Studies: CT scan, MRI, or X-rays to examine the GI tract.

Inflammatory Bowel Disease Market Key Facts

  • In 2023, the United States had the largest number of cases among the 7MM, with approximately 14 million prevalent cases. These numbers are anticipated to rise in the forecast period.

  • In the United States in 2023, irritable bowel syndrome was more prevalent among females than males in terms of total gender-specific cases.

  • In 2023, Germany had the highest prevalence of irritable bowel syndrome among the EU4 and the UK, whereas Spain reported the lowest number of cases.

Inflammatory Bowel Disease Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Inflammatory Bowel Disease Epidemiology, Segmented as –

  • Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM

  • Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM

  • Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) (e.g., Ulcerative colitis, Crohn’s Disease, and Unspecified) in the 7MM

  • Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM

  • Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM

  • Inflammatory Bowel Disease Drugs Uptake and Pipeline Development Activities

Learn How the Inflammatory Bowel Disease Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market

Inflammatory Bowel Disease Therapeutics Analysis

  • Blautix: CJ Bioscience/4D Pharma

  • BEKINDA (RHB-102): RedHill Biopharma

  • TRP-8802: Tryp Therapeutics

  • Mirikizumab: Eli Lilly and Company

  • Filgotinib: Gilead/ Galapagos

  • AMT-101: Applied Molecular Transport

  • PN-943: Protagonist Therapeutics

  • Tremfya: Janssen

  • Brazikumab: AstraZeneca

Leading Companies in the Inflammatory Bowel Disease Therapeutics Market Include:

  • Takeda

  • AstraZeneca 

  • Janssen Pharmaceuticals

  • Abbvie

  • Eli Lilly and Company

  • Applied Molecular Transport

  • Janssen

  • Gilead

  • Galapagos

Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market

Table of Contents

1. Key Insights

2. Executive Summary 

3. Inflammatory Bowel Disease Competitive Intelligence Analysis

4. Inflammatory Bowel Disease Market Overview at a Glance

5. Inflammatory Bowel Disease Disease Background and Overview

6. Inflammatory Bowel Disease Patient Journey

7. Inflammatory Bowel Disease Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Inflammatory Bowel Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Inflammatory Bowel Disease Unmet Needs

10. Key Endpoints of Inflammatory Bowel Disease Treatment

11. Inflammatory Bowel Disease Marketed Products

12. Inflammatory Bowel Disease Emerging Drugs and Latest Therapeutic Advances

13. Inflammatory Bowel Disease Seven Major Market Analysis

14. Attribute Analysis

15. Inflammatory Bowel Disease Market Outlook (In US, EU5, and Japan)

16. Inflammatory Bowel Disease Access and Reimbursement Overview

17. KOL Views on the Inflammatory Bowel Disease Market

18. Inflammatory Bowel Disease Market Drivers

19. Inflammatory Bowel Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/